malignant Sertoli-Leydig cell tumor

Integrated lineage evidence

Retain the morphology, ancillary results and specialist interpretation supporting the mixed tumor identity.

1. Which sampled areas demonstrate Sertoli differentiation, Leydig differentiation and associated stroma? definition
2. Which competing diagnosis remains plausible, and what morphology or ancillary result discriminates it? boundary
3. Which specimen and reviewing pathologist support the final integrated diagnosis? provenance

Basis of malignancy

Record the exact justification for the malignant label without requiring metastasis or treating every adverse feature as sufficient.

1. Which classification edition and diagnostic criteria justify calling this Sertoli-Leydig tumor malignant? definition
2. Does the record establish malignancy, describe malignant potential only, or leave behavior uncertain? boundary
3. What specialist review is needed if the behavior code and pathology narrative disagree? action

Representative differentiation

Document the differentiation assessment, variation across the tumor and adequacy of representation.

1. What differentiation category was assigned, and which architectural and cytological observations support it? definition
2. Were morphologically distinct solid, cystic and suspicious areas sampled sufficiently to support that assessment? provenance

Component-specific interpretation

Record retiform architecture separately from heterologous epithelial or mesenchymal tissue and its interpreted behavior.

1. Which retiform and heterologous components are present, and what proportion or distribution was reported? measurement
2. Which heterologous components are interpreted as benign or malignant, and what supports each interpretation? boundary
3. Could an overrepresented component have obscured Sertoli-Leydig differentiation in the original specimen? boundary

Stage and rupture evidence

Preserve primary site, extraovarian findings, capsule status and the completeness of staging.

1. Which findings establish the ovarian primary, laterality and any pelvic, peritoneal, nodal or distant involvement? measurement
2. Was rupture preoperative or intraoperative, and were surface involvement and washings assessed? provenance
3. Which FIGO stage is supported, and which missing observations prevent a firmer assignment? boundary

Individual secretory phenotype

Record symptoms, hormone measurements and their timing without presuming that every tumor is clinically androgenic.

1. What virilization, menstrual changes, pain or mass-related symptoms occurred, and when did they begin? measurement
2. Which hormones or markers were abnormal before treatment, using which assays and reference intervals? measurement
3. What evidence distinguishes tumor-associated androgen excess from another endocrine cause? boundary

Tumor variant interpretation

Preserve variant identity, laboratory interpretation and technical limitations without making a molecular result sufficient for diagnosis.

1. Which DICER1 variants were detected in which tumor specimen, with what assay coverage and laboratory classification? provenance
2. Does the molecular result support the integrated diagnosis, conflict with it or remain uninformative? boundary

Predisposition evidence and referral

Distinguish documented constitutional findings from tumor-only results, family history and unresolved testing.

1. Has constitutional DICER1 testing been performed, and what specimen, result and interpretive limitations were reported? provenance
2. What genetics review or additional evaluation is indicated under the applicable specialist guidance? action
3. Which findings belong to this tumor episode and which should link to a separate predisposition-syndrome record? boundary

Individualized management rationale

Record stage, histology, residual disease, fertility priorities and the evidence used by the treating team; pediatric guidance requires explicit assessment before application to adults. [NCI childhood ovarian treatment guidance](https://www.cancer.gov/types/ovarian/hp/child-ovarian-treatment-pdq)

1. What operation was performed, what reproductive structures remain, and what macroscopic or microscopic disease remains? measurement
2. How did stage, differentiation and any malignant heterologous component inform the specialist treatment decision? action
3. Which guideline or study supports the selected approach for this patient's age and tumor subtype? provenance

Longitudinal disease attribution

Link serial imaging, pathology and informative markers to dated disease assessments; retain uncertainty when a new lesion could represent recurrence or another primary.

1. Which clinical, imaging and individually informative marker findings support the current disease state? measurement
2. What comparison with the original pathology and molecular findings supports calling a new lesion recurrent Sertoli-Leydig tumor? boundary
3. What specialist surveillance plan and escalation triggers were agreed, including follow-up when baseline hormones were normal? action

Check these first

Recalled without web access and unsourced; every item is a lead to verify.

1. Which of these check these first hold for the sense of malignant Sertoli-Leydig cell tumor this model covers, and on what evidence? provenance

Kinds and varieties

Recalled without web access and unsourced; every item is a lead to verify.

1. Which of these kinds and varieties hold for the sense of malignant Sertoli-Leydig cell tumor this model covers, and on what evidence? provenance

Identifiers and schemes

Recalled without web access and unsourced; every item is a lead to verify.

1. Which of these identifiers and schemes hold for the sense of malignant Sertoli-Leydig cell tumor this model covers, and on what evidence? provenance

Standards and regulation

Recalled without web access and unsourced; every item is a lead to verify.

1. Which of these standards and regulation hold for the sense of malignant Sertoli-Leydig cell tumor this model covers, and on what evidence? provenance

Real-world use

Recalled without web access and unsourced; every item is a lead to verify.

1. Which of these real-world use hold for the sense of malignant Sertoli-Leydig cell tumor this model covers, and on what evidence? provenance

Failure modes and hazards

Recalled without web access and unsourced; every item is a lead to verify.

1. Which of these failure modes and hazards hold for the sense of malignant Sertoli-Leydig cell tumor this model covers, and on what evidence? provenance

Neighbouring kinds and how to tell them apart

Recalled without web access and unsourced; every item is a lead to verify.

1. Which of these neighbouring kinds and how to tell them apart hold for the sense of malignant Sertoli-Leydig cell tumor this model covers, and on what evidence? provenance